{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:50:13Z","timestamp":1761490213865,"version":"build-2065373602"},"reference-count":59,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.hoc.2016.11.002","type":"journal-article","created":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T16:52:35Z","timestamp":1490287955000},"page":"359-375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma"],"prefix":"10.1016","volume":"31","author":[{"given":"Enrica","family":"Marchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander G.","family":"Raufi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Owen A.","family":"O'Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2016.11.002_bib1","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.002_bib2","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma","volume":"117","author":"Foss","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.002_bib3","first-page":"443","article-title":"2016\u00a0US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.hoc.2016.11.002_bib4","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.002_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","article-title":"Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T\u00a0cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95","volume":"151","author":"Simon","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.11.002_bib6","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cncr.20999","article-title":"Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience","volume":"103","author":"Escalon","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2016.11.002_bib7","first-page":"18","article-title":"New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties","volume":"12","author":"Sirotnak","year":"1984","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.hoc.2016.11.002_bib8","first-page":"26","article-title":"New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models","volume":"12","author":"Sirotnak","year":"1984","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.hoc.2016.11.002_bib9","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1182\/blood.V116.21.4882.4882","article-title":"Pralatrexate is effective as second-line treatment following cyclophosphamide\/doxorubicin\/vincristine\/prednisone (CHOP) failure in patients with relapsed or refractory peripheral T-Cell lymphoma (PTCL)","volume":"116","author":"Shustov","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.002_bib10","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/1042819031000077124","article-title":"Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression","volume":"44","author":"Wang","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2016.11.002_bib11","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.002_bib12","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood.V116.21.1753.1753","article-title":"Pralatrexate is effective in patients with relapsed or refractory peripheral T-Cell lymphoma (PTCL) with prior ifosfamide, carboplatin, and etoposide (ICE)-based regimens","volume":"116","author":"Goy","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.002_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.002_bib14","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.002_bib15","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.002_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.hoc.2016.11.002_bib17","article-title":"Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma","author":"Pro","year":"2016","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.hoc.2016.11.002_bib18","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.13222","article-title":"A\u00a0Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma","volume":"168","author":"Foss","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.11.002_bib19","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) Study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.002_bib20","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.002_bib21","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.002_bib22","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.002_bib23","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","article-title":"Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study","volume":"32","author":"Fanale","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.002_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13554-013-0008-7","article-title":"Brentuximab vedotin in CD30+ lymphomas","volume":"3","author":"Perini","year":"2013","journal-title":"Biol Ther"},{"key":"10.1016\/j.hoc.2016.11.002_bib25","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.002_bib26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.2012.46.8793","article-title":"Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas","volume":"32","author":"Friedberg","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.002_bib27","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1200\/JCO.2014.60.6327","article-title":"Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108","volume":"33","author":"Barr","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl; abstr TPS8110","key":"10.1016\/j.hoc.2016.11.002_bib28","article-title":"Phase III study of investigational MLN8237 (alisertib) versus investigator\u201ds choice in patients (pts) with relapsed\/refractory (rel\/ref) peripheral T-cell lymphoma (PTCL)","volume":"30","author":"O'Connor","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.002_bib29","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial","volume":"31","author":"Damaj","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.002_bib30","doi-asserted-by":"crossref","first-page":"djt378","DOI":"10.1093\/jnci\/djt378","article-title":"Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients","volume":"106","author":"Gambacorti Passerini","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.hoc.2016.11.002_bib31","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMc1013224","article-title":"Crizotinib in anaplastic large-cell lymphoma","volume":"364","author":"Gambacorti-Passerini","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2016.11.002_bib32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc1511045","article-title":"Abrupt relapse of ALK-positive lymphoma after discontinuation of crizotinib","volume":"374","author":"Gambacorti-Passerini","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2016.11.002_bib33","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1365-2141.2010.08526.x","article-title":"Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation","volume":"152","author":"Chapuy","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.11.002_bib34","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/bjh.12944","article-title":"Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma","volume":"167","author":"Gibson","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.11.002_bib35","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrg1879","article-title":"The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism","volume":"7","author":"Engelman","year":"2006","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.hoc.2016.11.002_bib36","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1182\/blood.V124.21.803.803","article-title":"Duvelisib (IPI-145), a phosphoinositide-3-kinase-\u03b4,\u03b3 inhibitor, shows activity in patients with relapsed\/refractory T-cell lymphoma","volume":"124","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.002_bib37","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/bjc.1998.570","article-title":"In\u00a0vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells","volume":"78","author":"Depenbrock","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.hoc.2016.11.002_bib38","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3324\/haematol.2012.069757","article-title":"Multicenter phase II study of plitidepsin in patients with relapsed\/refractory non-Hodgkin's lymphoma","volume":"98","author":"Ribrag","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2016.11.002_bib39","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/imt.14.94","article-title":"Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas","volume":"6","author":"Remer","year":"2014","journal-title":"Immunotherapy"},{"key":"10.1016\/j.hoc.2016.11.002_bib40","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.002_bib41","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.002_bib42","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.002_bib43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc1111708","article-title":"TET2 and DNMT3A mutations in human T-cell lymphoma","volume":"366","author":"Couronne","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2016.11.002_bib44","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in Peripheral T\u00a0cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.hoc.2016.11.002_bib45","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A\u00a0targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.002_bib46","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood-2015-05-644591","article-title":"IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.002_bib47","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","article-title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma","volume":"119","author":"Cairns","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.002_bib48","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.002_bib49","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1158\/1078-0432.CCR-10-0671","article-title":"Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in\u00a0vitro and in\u00a0vivo models of T-cell lymphoid malignancies","volume":"16","author":"Marchi","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2016.11.002_bib50","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.1182\/blood-2011-02-336891","article-title":"HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL","volume":"118","author":"Kalac","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.002_bib51","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bjh.13566","article-title":"The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma","volume":"171","author":"Marchi","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.11.002_bib52","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-14-2249","article-title":"Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma","volume":"21","author":"Jain","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2016.11.002_bib53","first-page":"2552","article-title":"Development of novel backbones for the treatment of peripheral T-cell lymphoma (PTCL): the pralatrexate\/romidepsin doublet","volume":"34","author":"Amengual","year":"2016","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.hoc.2016.11.002_bib54","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1158\/1078-0432.CCR-15-0033","article-title":"Aurora A kinase inhibition selectively synergizes with histone deacetylase inhibitor through cytokinesis failure in T-cell lymphoma","volume":"21","author":"Zullo","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2016.11.002_bib55","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1182\/blood.V124.21.1744.1744","article-title":"A\u00a0Phase I trial of alisertib plus romidepsin for relapsed\/refractory aggressive B- and T-cell lymphomas","volume":"124","author":"Fanale","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.002_bib56","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/sj.onc.1208212","article-title":"Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia\/lymphoma","volume":"24","author":"Nasr","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.hoc.2016.11.002_bib57","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1073\/pnas.0503221102","article-title":"Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma","volume":"102","author":"Hideshima","year":"2005","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2016.11.002_bib58","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1016\/S2352-3026(15)00097-6","article-title":"Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial","volume":"2","author":"Tan","year":"2015","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.hoc.2016.11.002_bib59","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858816301708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858816301708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:05:06Z","timestamp":1760184306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858816301708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0889858816301708"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2016.11.002","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2016.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}